These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38462769)

  • 1. Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States.
    Oladipupo F; Stanek J; Walden J; Young J; Rose MJ; Nicol K; Villella A; Creary S
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30945. PubMed ID: 38462769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.
    Okam MM; Shaykevich S; Ebert BL; Zaslavsky AM; Ayanian JZ
    Med Care; 2014 Jul; 52(7):612-8. PubMed ID: 24926708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
    van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
    Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
    Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
    Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 10. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
    Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
    Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
    Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
    Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
    Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
    Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
    BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
    Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.